Krystal Biotech, Inc.

Equities

KRYS

US5011471027

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:13:29 2024-03-28 pm EDT 5-day change 1st Jan Change
178.3 USD +0.63% Intraday chart for Krystal Biotech, Inc. +5.30% +44.12%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing MT
Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Ease Late Afternoon MT
Sector Update: Health Care Stocks Weaker Monday Afternoon MT
Top Midday Gainers MT
Krystal Biotech Shares Jump After Surprise Q4 Profit MT
Krystal Biotech Swings to Q4 Profit as Company Generates Revenue; Shares Climb Pre-Bell MT
Transcript : Krystal Biotech, Inc., Q4 2023 Earnings Call, Feb 26, 2024
Krystal Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (KRYS) KRYSTAL BIOTECH Posts Q4 EPS $0.30, vs. Street Est of $-0.25 MT
Krystal Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Traders Await Inflation Data This Week DJ
MORNING BID AMERICAS-Booming stocks step back as PCE hoves into view RE
Krystal Biotech Says FDA Grants Fast Track Designation to Inhaled KB707 for Lung Tumors Treatment MT
Krystal Biotech Secures J-code for Vyjuvek MT
Krystal Biotech Receives Permanent J-Code for VYJUVEK® CI
Krystal Biotech Says Japan Grants Orphan Drug Designation to Skin Disease Treatment; Shares Rise Pre-Bell MT
Krystal Biotech Insider Sold Shares Worth $5,283,291, According to a Recent SEC Filing MT
Krystal Biotech Insider Sold Shares Worth $5,283,291, According to a Recent SEC Filing MT
Krystal Biotech Says European Regulator Validates Marketing Authorization Application for Skin Disease Treatment MT
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for Vyjuvek for the Treatment of Dystrophic Epidermolysis Bullosa CI
Sector Update: Health Care Stocks Advance Premarket Monday MT
Transcript : Krystal Biotech, Inc., Q3 2023 Earnings Call, Nov 06, 2023
Krystal Biotech Swings to Profit in Q3; Generates Revenue MT
Krystal Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Chart Krystal Biotech, Inc.
More charts
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patient’s skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
177.2 USD
Average target price
185.9 USD
Spread / Average Target
+4.91%
Consensus
  1. Stock
  2. Equities
  3. Stock Krystal Biotech, Inc. - Nasdaq
  4. News Krystal Biotech, Inc.
  5. Krystal Biotech : Completes Enrollment of Phase 3 Study of B-VEC to Treat Dystrophic Epidermolysis Bullosa